(0.10%) 5 253.66 points
(0.06%) 39 785 points
(0.00%) 16 399 points
(1.52%) $82.59
(0.58%) $1.728
(2.04%) $2 235.20
(0.71%) $24.93
(1.35%) $922.00
(0.28%) $0.926
(0.68%) $10.84
(0.04%) $0.792
(0.17%) $92.59
Live Chart Being Loaded With Signals
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome...
Stats | |
---|---|
Today's Volume | 373 711 |
Average Volume | 532 276 |
Market Cap | 2.70B |
EPS | $0 ( 2024-02-21 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 17.68 |
ATR14 | $0.0280 (0.13%) |
Volume Correlation
Neuren Pharmaceuticals Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Neuren Pharmaceuticals Correlation - Currency/Commodity
Neuren Pharmaceuticals Financials
Annual | 2023 |
Revenue: | $231.93M |
Gross Profit: | $231.93M (100.00 %) |
EPS: | $1.240 |
Q4 | 2023 |
Revenue: | $169.00M |
Gross Profit: | $169.00M (100.00 %) |
EPS: | $0.860 |
Q2 | 2023 |
Revenue: | $62.93M |
Gross Profit: | $51.84M (82.38 %) |
EPS: | $0.380 |
Q4 | 2022 |
Revenue: | $14.55M |
Gross Profit: | $14.55M (99.96 %) |
EPS: | $0.0575 |
Financial Reports:
No articles found.
Neuren Pharmaceuticals
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators